A recent study found that even when people with hepatitis C prematurely stopped direct-acting antiviral therapy, they were still able to achieve a sustained virological response. Over time, hepatitis C can lead to liver fibrosis (scarring), cirrhosis and hepatocellular carcinoma, the most common type of liver cancer. Some people with hepatitis C prematurely discontinue their antiviral therapy for a variety of reasons, but few studies have assessed the impact of shorter treatment duration. Of the total, 251 (69%) had liver cirrhosis. Click here to learn more about treating hepatitis C.